Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ibutilide Fumarate (U70226E) is the fumarate salt form of ibutilide, a class III antiarrhythmic agent. Ibutilide exerts its effect by activating a slow, inward, predominately sodium current rather than by blocking outward potassium currents. This results in prolongation of atrial and ventricular action potential duration and refractory periods. Ibutilide slightly decreases the sinus rate and atrioventricular (AV) conduction and produces a dose-related prolongation of the QT interval.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
10 mg | 在庫あり | ¥ 11,500 | |||
25 mg | 在庫あり | ¥ 18,500 | |||
50 mg | 在庫あり | ¥ 22,500 | |||
100 mg | 在庫あり | ¥ 41,000 | |||
200 mg | 在庫あり | ¥ 62,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,500 |
説明 | Ibutilide Fumarate (U70226E) is the fumarate salt form of ibutilide, a class III antiarrhythmic agent. Ibutilide exerts its effect by activating a slow, inward, predominately sodium current rather than by blocking outward potassium currents. This results in prolongation of atrial and ventricular action potential duration and refractory periods. Ibutilide slightly decreases the sinus rate and atrioventricular (AV) conduction and produces a dose-related prolongation of the QT interval. |
別名 | Corvert Fumarate, U70226E |
分子量 | 885.23 |
分子式 | (C20H36N2O3S)2·C4H4O4 |
CAS No. | 122647-32-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/ml (56.48 mM), Sonication is recommended
DMSO: 50 mg/ml (56.48 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ibutilide Fumarate 122647-32-9 Membrane transporter/Ion channel Metabolism Calcium Channel Sodium Channel Ibutilide antiarrhythmia agent Potassium Channel inhibit Corvert Fumarate Inhibitor U70226E long QT syndrome P-glycoprotein K+ current pharmacology KcsA ATP-binding cassette transporters inhibitor